Organic Active Ingredients TRIZ Cases

Mesothelin-binding antibodies use cleavable eribulin linkers to kill cancer cells while limiting toxicity to normal tissues.

Controlled chlorination and solvent precipitation improve purity and yield of a URAT1 inhibitor while easing separation for safer uric acid lowering.

A torus-like DNA mazzocchio uses modular linkers and fewer oligonucleotides to encapsulate diverse cargos with stable, biocompatible delivery.

A buffered epinephrine formulation with metabisulfite and EDTA limits oxidation and impurities, preserving potency during long-term storage.

Selective Helios degraders tune substituent patterns to improve IKZF2 degradation, metabolic stability, and reduced off-target effects.

Antibody-drug conjugates link anti-influenza antibodies with VX-787 or baloxavir payloads to broadly neutralize influenza A subtypes.

A phosphorus-containing SOS1 inhibitor uses a quinazoline-phosphonic acid scaffold to block RAS activation and ERK phosphorylation.

Galacto- and fructo-oligosaccharides directly suppress nasal epithelial chemokines to treat underlying non-allergic rhinitis inflammation.

Fluorinated cationic lipids in lipid nanoparticles protect nucleic acids from plasma degradation while improving intracellular delivery and tolerability.

Gapmer oligonucleotides target human SNHG14 RNA to restore paternal UBE3A in neurons while limiting effects on SNORD115 and SNRPN.

A chimpanzee adenovirus vector delivers patient-specific tumor neoantigens while avoiding pre-existing human vector immunity and improving immune targeting.

Antibody-conjugated cyclic dinucleotides resist degradation and deliver stronger, targeted STING activation for anti-tumor and immune response.

Small molecules bind the WASp WH1 domain to block degradation, restore immune cell function, and avoid transplant and gene therapy risks.

An anti-CD37 antibody-drug conjugate paired with R-CHOP, R-CHP, alkylating, or immunomodulatory drugs improves combination efficacy in resistant B-cell cancers.

Enteric-coated losartan mini-tablets replace unstable pediatric suspensions with precise dosing, better swallowability, and bitter taste masking.

Engineered u-PA variants selectively cleave complement C3 to inhibit complement activation while reducing activity on plasminogen.

Engineered guide RNAs recruit endogenous ADAR to edit target RNA precisely, avoiding exogenous protein delivery and immunogenicity risks.

Selective CYP11A1 inhibitors block steroid hormone synthesis to suppress hormone-refractory prostate tumor growth with fewer side effects.

Novel evenamide hydrochloride crystal forms balance solubility with moisture stability, enabling pure, non-hygroscopic pharmaceutical formulations.

Antigen-primed dendritic cells combined with IFN-α and TLR agonists boost T-cell polarization and CD8+ CTL activation near diseased tissue.

A citrate crystal form improves stability, solubility, and bioavailability while lowering hygroscopicity for 5-HT2-targeted antipsychotic use.

Controlled 0.5-10 μm inhaled magnesium isoglycyrrhizinate improves pulmonary deposition, bioavailability, and side-effect profile.

A stable peptide inhibits hyaluronidase and reactive oxygen species to extend hyaluronic acid filler duration while supporting skin cell activation.

Local delivery of a pro-chondrogenic osteoarthritis compound relieves joint pain and slows cartilage degeneration with fewer systemic side effects.

Topical phentolamine constricts the pupil to improve near and far vision in presbyopia and mydriasis with once-daily dosing.

Ginkgo biloba terpene lactone compositions address the lack of tremor therapies, improving essential and vascular tremor without adverse reactions.

Novel naphthyridine MEK inhibitors are tuned to cross the blood-brain and blood-CSF barriers while maintaining CNS tumor treatment efficacy.

Phenolic glycolipid derivatives improve Mincle activation to boost TNF, INF-γ, and antibody responses with lower toxicity risk.

Small-molecule PD-L1 inhibitors block PD-1 signaling to boost immune response in HCC and help inhibit HBV and HDV replication.

A nanocrystalline darolutamide form raises solubility eightfold and improves bioavailability, enabling lower doses with stable solid-state properties.

Targeting ERβ expression or ERβ-TP53 binding creates a receptor-based treatment route for triple-negative breast cancer cells.

A quinoline derivative approach for advanced nasopharyngeal carcinoma that reduces tumor size and metastasis after prior chemo or radiotherapy.

Semi-saturated bicyclic compounds tune drug-like properties while inhibiting DNA polymerase Θ to improve treatment options for HR-deficient tumors.

A PRP-based composition boosts bone marrow endogenous cell proliferation to improve musculoskeletal repair, joint function, pain, and motion.

Screened parent lines and doubled haploid breeding raise S-methylmethionine in Brassica oleracea to improve nutritional value.

Novel covalent IDH1 and IDH2 mutant inhibitors improve selectivity and activity to lower D-2HG and support treatment of IDH-driven tumors.

Mobilizing bone marrow cells into peripheral blood enables apheresis-based HSC collection from deceased donors with less contamination and body disruption.

Methionine acts as a sacrificial antioxidant in aqueous insulin formulations, limiting oxidation, haze, and protein aggregation over time.

ATM inhibition activates cGAS/STING to boost T-cell infiltration and improve immune checkpoint therapy across more cancer patients.

Lyophilized pooled fetal support tissue preserves HC-HA/PTX3 and other bioactive factors, improving product uniformity and potency.

Amorphous dasatinib dispersions with polymers maintain drug delivery despite acid-reducing agents and elevated gastric pH, reducing PK variability.

A stable aqueous IV nicotinamide riboside formulation raises cellular NAD+ while minimizing pain, inflammation, and discomfort.

DCAF15-recruiting sulfonamides selectively degrade RRM proteins to target RNA splicing in cancer while reducing off-target toxicity.

Alternative bumetanide delivery through nasal, sublingual, or subcutaneous routes restores diuresis when oral absorption fails.

Fixed antibiotic dosing in overweight and obese patients avoids unreliable weight-based calculations, lowering toxicity while maintaining cure rates.

STRO-1+ multipotential cells are delivered to degenerate intervertebral discs to restore disc height and improve disc health markers.

Using R-ketamine without S-ketamine preserves rapid, sustained antidepressant effects while reducing psychotomimetic side effects.

Blocking IL-31 or JAK interrupts the itch pathway triggered by FXR agonists, helping preserve liver therapy while reducing pruritus.

Specific oral testosterone dosing, alone or with d-alpha tocopherol, improves NASH liver fat, inflammation, and fibrosis with minimal adverse effects.

Biomarker-guided ANAVEX2-73 dosing helps relieve Rett syndrome symptoms while limiting adverse events and easing administration.

Salt formation and controlled crystallization improve the stability and pharmaceutical usability of a naphthyridine amide compound for clinical use.

A probiotic-prebiotic blend with hyaluronic acid helps rebalance gut flora while strengthening intestinal barrier function and hydration.

Chiral imidazopiperazine compounds improve selective CBP/P300 bromodomain inhibition to modulate gene expression in proliferative disease.

Combining a thioether-linked anti-CDH6 ADC with a VEGF inhibitor boosts tumor suppression while maintaining a safe treatment profile.

Alkalinizing agents raise GI pH to speed pitolisant or doxepin absorption, shortening Tmax and increasing peak plasma exposure.

A new sulfonamide class is paired with taxanes or vinca alkaloids to improve cancer treatment and help reduce recurrence risk.

Altered stable isotope ratios with deuterium-depleted water suppress degeneration by influencing cellular function, DNA repair, and protein synthesis.

Pre-formulated hydromorphone in buffered sodium chloride IV bags avoids compounding errors and maintains sterility and stability for room-temperature storage.

Timed short-acting CDK4/6 inhibitor dosing shields immune cells during chemotherapy, improving checkpoint inhibitor response and durable antitumor immunity.

A hot-melt extruded copolymer matrix enables humidity-resistant, pH-independent pyridostigmine release with strength and bioequivalent sustained delivery.

Timed oral edaravone dosing after high-fat, standard, or light meals stabilizes absorption and drug levels for more consistent treatment.

ABCG2 inhibition reduces PPIX efflux to limit skin and liver exposure, helping treat phototoxicity and hepatotoxicity in EPP and XLP.

Modulating U1 snRNP protects nascent transcripts from premature polyadenylation, reshaping mRNA isoforms and oncogenicity.

Capsid-binding compounds crosslink conserved viral proteins to block particle release and deliver broad RNA virus activity with low cytotoxicity.

Bifunctional compounds recruit IRAK4 to VHL, CRBN, or IAP ligases to drive ubiquitination and proteasomal degradation for disease treatment.

Using basic pH above 7, this case improves lipoxin A4 mimetic yield and stability while reducing synthesis and stabilization cost.

Modified oligonucleotides bind PMP22 transcripts to lower expression, helping relieve Charcot-Marie-Tooth disease symptoms.

ASOs raise SynGAP protein by blocking miRNA interference, easing 5′-UTR repression, and depleting antisense lncRNAs.

Crystalline polymorphs of an SHP2 inhibitor improve therapeutic effectiveness while enabling solid-form selection for stability and manufacturing.

A stable crystalline Form 2 replaces the hygroscopic amorphous solid, enabling ambient storage and easier pharmaceutical handling.

Bioreducible polymer particles and gels enable stable peptide or siRNA delivery with tunable release through hydrolysis, enzymes, and disulfide reduction.

Microfluidic mixing and solvent removal enable scalable RNA liposome production with controlled size, high encapsulation efficiency, and preserved activity.

Prodrug modification improves solubility, stability, and bioavailability of Tyk2 modulators for broader dosing and formulation in autoimmune therapy.

Novel aldose reductase inhibitors are tuned to cross the blood-brain barrier and reduce ROS-driven infarct damage in ischemic stroke.

Crystalline and amorphous Bcl-2/Bcl-xL inhibitor forms use controlled crystallization to improve solubility, stability, and bioavailability.

Controlled Form VI crystallization improves maribavir synthesis yield to at least 45% while lowering impurities for oral formulations.

Oxygenated phosphonic acid derivatives inhibit PI3K/Akt to suppress inflammation and mast cell degranulation with low cytotoxicity.

Targeted DUX4-binding polynucleic acid conjugates improve RNAi uptake and stability while reducing immune stimulation in FSHD treatment.

BRD9-targeting compounds reduce BRD9 levels and activity to treat BAF-related cancers and infections with one therapeutic mechanism.

A self-emulsifying abiraterone acetate composition forms an O/W nanoemulsion in the gut to raise oral absorption and reduce food-related variability.

Cyclic IL-22 dimer therapy targets gut epithelial recovery in GvHD while limiting the immune-function tradeoff of standard immunosuppression.

By blocking MAST1, MEK activation, and HSP90 support, this combination therapy restores platinum drug sensitivity in resistant cancer cells.

Chk1 inhibitor compounds block cell cycle checkpoints and DNA repair, boosting DNA-damaging cancer therapy while preserving treatment selectivity.

A PPARα-agonist compound lowers blood LDL-C when statins fall short or cause side effects, expanding treatment options for hypercholesterolemia.

Broad-spectrum Formula I compounds inhibit multiple KRas mutations and help bypass resistance seen with existing KRas G12C inhibitors.

An HPMC-AS rifaximin solid dispersion improves cirrhosis treatment by reducing hospitalization time, mortality, and refractory ascites.

Selective norepinephrine inhibition with reboxetine reduces cataplexy attacks and improves sleep quality without DEA scheduling burdens.

A transcription factor composition restores cellular viability and epigenetic function while avoiding c-Myc-related safety risks and teratoma formation.

Specific β1-3 Gal-Gal oligosaccharide ratios reduce branched short-chain fatty acids while supporting gut microbiota health in high-protein diets.

By inhibiting PHD-mediated HIF hydroxylation, these compounds boost erythropoietin synthesis and iron metabolism to improve anemia treatment.

Isolated CTGF and TGFβ1 replace heterogeneous NCCM to restore disc matrix, reduce pain, and promote regenerative repair.

A four-drug ACT regimen combines sublingual artemether, artesunate, berberine, and primaquine to overcome resistance and prevent malaria relapse.

Purified S. epidermidis lipoteichoic acid modulates TLR2-linked immune pathways to reduce tactile allodynia and inflammation in CPPS and arthritis.

Single-step resorbable nonwoven implant pouches enable tissue ingrowth and antibiotic elution while avoiding bacteria-trapping multifilament fabrics.

Sarmentosin esters reversibly inhibit MAO-A and MAO-B to modulate neurotransmitters while avoiding the side effects of irreversible MAO inhibitors.

A hyaluronic acid ester hydrogel carries zinc gluconate in soluble form, improving residence time and viscoelasticity for topical and injectable use.

Carbon-coated biocompatible nanospheres stabilize single-strand RNA at 0°C to 25°C, preserving integrity during storage and transport.

An anti-transferrin receptor RNA conjugate improves cellular uptake, blood stability, and DMPK silencing for DM1 treatment.

A lenacapavir free-acid formulation with PEG 300, water, and ethanol enables once-yearly HIV PrEP to improve adherence and access.

Defined benzene-ring substitutions expand PI3K inhibitor structures to improve cancer treatment selectivity while reducing toxic side effects.